Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer.
Amplification of the HER2 (ErbB2, c-Neu) proto-oncogene in breast cancer is associated with poor prognosis and high relapse rates. HER2/ErbB2, in conjunction with ErbB3, signals through the Akt/phosphatidylinositol 3-kinase pathway and leads to the activation of mammalian target of rapamycin (mTOR), a critical mRNA translation regulator that controls cell growth. Gene expression analysis of mammary tumors collected from mouse mammary tumor virus-c-Neu transgenic mice revealed that mRNA levels of several mTOR pathway members were either up-regulated (p85/phosphatidylinositol 3-kinase and p70S6 kinase) or down-regulated (eIF-4E-BP1) in a manner expected to enhance signaling through this pathway. Treatment of these mice with the mTOR inhibitor rapamycin caused growth arrest and regression of primary tumors with no evidence of weight loss or generalized toxicity. The treatment effects were due to decreased proliferation, associated with reduced cyclin D1 expression, and increased cell death in primary tumors. Whereas many of the dead epithelial cells had the histopathologic characteristics of ischemic necrosis, rapamycin treatment was not associated with changes in microvascular density or apoptosis. Rapamycin also inhibited cellular proliferation in lung metastases. In summary, data from this preclinical model of ErbB2/Neu-induced breast cancer show that inhibition of the mTOR pathway with rapamycin blocks multiple stages of ErbB2/Neu-induced tumorigenic progression.
Mosley
Jonathan D
JD
Department of Pharmacology, CWRU School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106-4965, USA.
Poirier
John T
JT
Seachrist
Darcie D
DD
Landis
Melissa D
MD
Keri
Ruth A
RA
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D016923:Cell Death / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D004789:Enzyme Activation / Q000187:drug effects; D004848:Epithelium / Q000473:pathology; D006965:Hyperplasia; D008175:Lung Neoplasms / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000098:blood supply / Q000201:enzymology / Q000473:pathology*; D008324:Mammary Tumor Virus, Mouse; D051379:Mice; D008822:Mice, Transgenic; D011494:Protein Kinases / Q000378:metabolism; D051381:Rats; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases
D000903:Antibiotics, Antineoplastic; D011494:Protein Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; C546843:mTOR protein, mouse
Cancer Res. 2007 Jan 1;67(1):167-77
17210696
Cancer Res. 2005 Jun 15;65(12):5325-36
15958580
Nat Med. 2002 Feb;8(2):128-35
11821896
Clin Cancer Res. 2004 Mar 15;10(6):2109-19
15041732
Pathol Oncol Res. 2001;7(3):190-6
11692145
Oncogene. 2001 Nov 8;20(51):7551-62
11709727
Oncogene. 1993 Nov;8(11):3037-42
7692372
Cancer Cell Int. 2003 Feb 18;3(1):2
12633504
Blood. 2005 Jun 1;105(11):4463-9
15671443
Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94
15342917
CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
14974761
Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16
16829981
Cancer Res. 2006 Jun 1;66(11):5549-54
16740688
J Cell Physiol. 2000 Feb;182(2):150-62
10623878
Mol Cell. 2006 Apr 21;22(2):159-68
16603397
Pharmacol Res. 2004 Dec;50(6):545-9
15501691
Science. 1987 Jan 9;235(4785):177-82
3798106
Cell Mol Biol Lett. 2005;10(3):479-98
16217558
Cancer Res. 2006 Feb 15;66(4):2028-37
16489002
J Clin Oncol. 2005 Aug 10;23(23):5314-22
15955899
Biochem Pharmacol. 2002 Sep;64(5-6):827-36
12213576
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6967-72
12011455
Mol Cell Biol. 2001 Mar;21(5):1540-51
11238891
Cancer Res. 2006 Jan 15;66(2):1070-80
16424043
Clin Cancer Res. 2006 Apr 15;12(8):2613-21
16638874
Int J Cancer. 1999 May 17;81(4):588-91
10225449
J Mammary Gland Biol Neoplasia. 1999 Jan;4(1):105-22
10219910
EMBO J. 1999 Apr 15;18(8):2149-64
10205169
Clin Cancer Res. 2004 Feb 1;10(3):1013-23
14871980
J Biol Chem. 1999 Sep 17;274(38):26776-82
10480882
Cell. 1988 Jul 1;54(1):105-15
2898299
Kidney Int. 2003 Mar;63(3):917-26
12631072
Exp Cell Res. 2003 Mar 10;284(1):54-65
12648465
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):293-300
14734482
Endocr Relat Cancer. 2001 Sep;8(3):249-58
11566616
Oncogene. 2005 Aug 4;24(33):5173-90
15897883
Oncogene. 2004 Apr 19;23(18):3189-99
15094768
Nat Rev Cancer. 2007 May;7(5):389-97
17446858
Nature. 2001 Jun 28;411(6841):1017-21
11429595
J Biol Chem. 2007 May 11;282(19):14056-64
17360704
Clin Cancer Res. 2004 Oct 15;10(20):6779-88
15501954
FASEB J. 2002 Jun;16(8):771-80
12039858
Cancer Res. 2006 Feb 1;66(3):1500-8
16452206
J Cell Physiol. 1999 Feb;178(2):235-46
10048588
Mol Endocrinol. 2006 Oct;20(10):2369-81
16772532
Oncogene. 2006 Jun 8;25(24):3408-23
16186809
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82
1359541